ACRV

Insider Trades

Name	Value	Action	Price	Current Price
Blume-Jensen PeterDirector, Officer: President And CEO $82k49k shares BuyJan 14, 2026 $1.68 --
Levy Adam D.Chief Financial Officer $15k8.8k shares BuyJan 14, 2026 $1.70 --
Devroe EricChief Operating Officer $17k10k shares BuyJan 13, 2026 $1.72 --
Perceptive Advisors LLC10 Percent Owner $401k298.9k shares SellMay 1, 2025 $1.34 --
Perceptive Advisors LLC10 Percent Owner $617k437.9k shares SellApr 30, 2025 $1.41 --
Perceptive Advisors LLC10 Percent Owner $353k250k shares SellApr 29, 2025 $1.41 --

News

globenewswire.comAcrivon Therapeutics to Present at TD Cowen's 7th Annual Oncology Innovation Summitglobenewswire.comMay 21

globenewswire.comAcrivon Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)globenewswire.comMay 15

globenewswire.comAcrivon Reports First Quarter 2026 Financial Results and Highlights Progress Towards Key 2026 Clinical Catalystsglobenewswire.comMay 13

globenewswire.comAcrivon to Highlight Preclinical Data with Three Posters at AACR Demonstrating Strong ACR-368 and ACR-2316 Synergies with Immune Checkpoint Inhibitors and ADC Payloads, Revealing Broad Clinical Development Opportunitiesglobenewswire.comApr 17

globenewswire.comAcrivon Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)globenewswire.comApr 15

Trade ACRV

About Acrivon Therapeutics, Inc. Common Stock

Acrivon Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company primarily focused on creating oncology treatments. The firm employs a unique strategy to identify patients whose tumors are predicted to be sensitive to specific medications, utilizing its proprietary proteomics-based platform for patient identification. This advanced system, named Acrivon Predictive Precision Proteomics (AP3), serves as a precision medicine tool. It is instrumental in developing drug-specific OncoSignature companion diagnostics, which are designed to pinpoint individuals most likely to benefit from the company's therapeutic candidates. Acrivon's flagship clinical asset is ACR-368, a selective small molecule inhibitor that targets both CHK1 and CHK2. This candidate is currently undergoing a potentially pivotal Phase 2 trial for a range of advanced tumor types, notably including platinum-resistant ovarian, endometrial, and bladder cancers. Beyond its lead program, the company is also cultivating several early-stage pipeline programs. These initiatives concentrate on crucial regulatory points within the DNA damage response and cell cycle regulation pathways, specifically identifying targets such as the protein kinases WEE1 and PKMYT1. Established in 2018, Acrivon Therapeutics, Inc. maintains its headquarters in Watertown, Massachusetts.

CEO: Peter Blume-Jensen
IPO Date: Nov 15, 2022

Market Data

Open: $1.54
High: $1.60
Low: $1.51
Volume: 677.6K
Avg Volume: 603.8K
52W High: $3.56
52W Low: $1.15

Valuation

Market Cap: $50M
Enterprise Value: $18M
Dividend Yield: 0.00%

Financials

Free Cash Flow: $-65M
Revenue: $0
Net Income: $-78M
Cash: $41M
Debt: $2.7M

Events

EarningsAug 12

EPS est. -0.48